Global Nicotine Gum Market

Nicotine Gum Market Size, Share, Growth Analysis, By Type (2mg, and 4mg), By Distribution Channel (Supermarkets/hypermarkets, Convenience stores), By Region - Industry Forecast 2024-2031


Report ID: SQSG35I2048 | Region: Global | Published Date: October, 2024
Pages: 157 | Tables: 64 | Figures: 75

Nicotine Gum Market News

  • In October 2022, the Department of Health in England launched vaping and smoking campaign— Stoptober.
  • In July 2021, Fertin Pharma was acquired by Philip Morris International. Fertin Pharma develops and manufactures pharmaceutical and well-being products using oral and intra-oral delivery systems.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Nicotine Gum Market size was valued at USD 1.30 billion in 2022 and is poised to grow from USD 1.37 billion in 2023 to USD 2.12 billion by 2031, growing at a CAGR of 5.6% in the forecast period (2024-2031).

Global nicotine gum market is highly competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'Johnson & Johnson (US) ', 'Novartis AG (Switzerland) ', 'ITC Limited (India) ', 'Cipla Health Limited (India) ', 'Perrigo Company plc (Ireland) ', 'Teva Canada (Canada) ', 'Philip Morris International Inc. (US) ', 'British American Tobacco PLC (UK) ', 'GlaxoSmithKline plc (UK) ', 'Novartis Consumer Health (Germany) ', 'Fertin Pharma (Denmark) ', 'Alchem International (India) ', 'Revolymer (UK) ', 'Pfizer Inc. (US) ', 'Cambrex Corporation (US) ', 'Reynolds American (US) ', 'Takeda Pharmaceutical Company (Japan)'

The rising prevalence of diseases such as lung cancer, heart disease, and respiratory problems is driving the market. In reality, it is caused by rising tobacco use in unique ways that endangers global public safety. Such factor could propel the nicotine gum market forward.

In the coming years, the market will benefit from increased health consciousness and a transition toward a healthier lifestyle. The government's emphasis on lowering smoking rates has increased significantly. Governments in all regions support broad approaches to tobacco control, along with a variety of actions such as a ban on tobacco promotion and advertising. It includes gradually increasing tobacco taxes in conjunction with measures to combat smuggling, which may limit smoking in the working place and public places.

North America has seen an increase in the percentage of health-conscious consumers, which has been bolstered by campaigns and government initiatives, propelling regional market growth. Furthermore, the region is home to significant brands that are focusing on product innovation in order to capitalise on rising demand and gain a competitive edge in the market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Nicotine Gum Market

Report ID: SQSG35I2048

$5,300
BUY NOW GET FREE SAMPLE